We evaluated the susceptibility of 100 Japanese Clostridium difficile isolates to fidaxomicin, a new macrocyclic antibiotic. The minimum inhibitory concentration (MIC) range of fidaxomicin was 0.03-0.5 μg/mL, with a MIC for inhibition of 50% (MIC) of 0.12 μg/mL, and for inhibition of 90% (MIC) of 0.25 μg/mL. We also evaluated the susceptibilities of the same 100 C. difficile isolates to vancomycin, metronidazole, moxifloxacin, clindamycin, meropenem, and ampicillin. Of all the antibiotics tested, fidaxomicin showed the most potent antimicrobial activity against this group of C. difficile isolates. MIC levels against C. difficile isolates, including those producing binary toxin, did not substantially differ from those previously reported in Europe, North America and Taiwan.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jiac.2017.04.008 | DOI Listing |
Dig Dis Sci
December 2021
Department of Medicine, Division of Digestive and Liver Diseases, New York Presbyterian Columbia University Medical Center, New York, NY, USA.
Background: Gastrointestinal symptoms are common in patients with COVID-19, but prevalence of co-infection with enteric pathogens is unknown.
Aims: This study assessed the prevalence of enteric infections among hospitalized patients with COVID-19.
Methods: We evaluated 4973 hospitalized patients ≥ 18 years of age tested for COVID-19 from March 11 through April 28, 2020, at two academic hospitals.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!